Conformationally restricted polyamine analogs as disease therapies
First Claim
1. A composition comprising a porphyrin-polyamine conjugate or porphyrin-polyamine analog conjugate, wherein the conjugate comprises a polyamine compound or polyamine analog compound covalently linked to a porphyrin compound, and a pharmaceutically acceptable carrier, wherein the composition comprises a therapeutic amount of the porphyrin-polyamine conjugate or porphyrin-polyamine analog conjugate for treatment of cancer or uncontrolled cell proliferation, and with the proviso that the polyamine or polyamine analog is not spermine, and the proviso that the polyamine or polyamine analog does not have a tertiary amino group.
2 Assignments
0 Petitions
Accused Products
Abstract
Novel conformationally restricted polyamine analogs are provided, as well as compositions comprising these novel polyamine analogs. Methods of using the novel polyamine analogs in treatment of diseases such as cancer are also provided. Also provided is a method of delivering these analogs specifically to tumor cells by covalently attaching polyamine analogs to porphyrin compounds, along with novel polyamine-porphyrin covalent conjugates.
131 Citations
20 Claims
- 1. A composition comprising a porphyrin-polyamine conjugate or porphyrin-polyamine analog conjugate, wherein the conjugate comprises a polyamine compound or polyamine analog compound covalently linked to a porphyrin compound, and a pharmaceutically acceptable carrier, wherein the composition comprises a therapeutic amount of the porphyrin-polyamine conjugate or porphyrin-polyamine analog conjugate for treatment of cancer or uncontrolled cell proliferation, and with the proviso that the polyamine or polyamine analog is not spermine, and the proviso that the polyamine or polyamine analog does not have a tertiary amino group.
- 3. A porphyrin-polyamine conjugate or porphyrin-polyamine analog conjugate of the formula
- 19. A composition comprising a porphyrin-polyamine analog conjugate, wherein the conjugate comprises a polyamine analog compound covalently linked to a porphyrin compound, and a pharmaceutically acceptable carrier, wherein the composition comprises a therapeutic amount of the porphyrin-polyamine analog conjugate for treatment of cancer or uncontrolled cell proliferation, and with the proviso that the polyamine analog is conformationally restricted.
Specification